Variable hsCRP (mg/L) | Quartiles of baseline hsCRP | p ANOVA | |||
---|---|---|---|---|---|
1st quartile 0.00–0.90 | 2nd quartile 0.90–2.15 | 3rd quartile 2.15–4.50 | 4th quartile 4.50–15.80 | ||
Age (year) | 66±10 | 67±10 | 69±9 | 68±9 | <0.001 |
Female sex (n, %) | 144 (34.1) | 142 (34.5) | 162 (41.8) | 178 (44.9) | 0.002 |
Smoking (n, %) | |||||
Current | 62 (14.7) | 77 (18.7) | 74 (19.1) | 91 (23) | 0.03 |
Former | 150 (35.5) | 147 (35.7) | 144 (37.1) | 143 (36.1) | 0.97 |
Never | 210 (49.8) | 188 (45.6) | 170 (43.8) | 162 (40.9) | 0.08 |
Hypertension | 342 (81) | 355(86.2) | 338(87.1) | 362(91.4) | <0.001 |
Randomised treatment (n, %) | 207 (49.1) | 219 (53.2) | 214 (55.2) | 180 (45.5) | 0.03 |
Systolic BP (mm Hg) | 143±0 | 146±20 | 144±20 | 146±20 | 0.045 |
Diastolic BP (mm Hg) | 81±10 | 83±10 | 82±11 | 82±10 | 0.36 |
Body mass index (kg/m2) | 25±4 | 27±4 | 28±4 | 29±5 | <0.001 |
Left ventricular mass index (g/m2) | 99.26±30.3 | 102.07±30.72 | 102.6±32.89 | 104.6±32.62 | 0.12 |
Left ventricular ejection fraction (%) | 66.41±8.21 | 65.71±8.54 | 65.33±7.76 | 65.43±8.53 | 0.25 |
Aortic valve area index (cm2/m2) | 0.73±0.27 | 0.69±0.28 | 0.68±0.26 | 0.68±0.25 | 0.046 |
Aortic valve peak velocity (m/s) | 3.25±0.64 | 3.24±0.65 | 3.27±0.65 | 3.25±0.64 | 0.96 |
Concomitant treatment | |||||
ACE inhibitor | 80 (19) | 126 (30.6) | 108 (27.8) | 134 (33.8) | <0.001 |
Angiotensin II receptor blocker | 72 (17.1) | 82 (19.9) | 67 (17.3) | 86 (21.7) | 0.272 |
Calcium antagonist | 83 (19.7) | 111 (26.9) | 111 (28.6) | 152 (38.4) | <0.001 |
Aspirin or other platelet inhibitor | 182 (43.1) | 182 (44.2) | 164 (42.3) | 191 (48.2) | 0.34 |
β-Blocker | 173 (41) | 212 (51.5) | 202 (52.1) | 208 (52.5) | 0.002 |
ANOVA, analysis of variance; BP, blood pressure; hsCRP, high-sensitive C reactive protein.